Remote vital sign monitoring company Current Health (formerly snap40) has completed an $11.5 million Series A round of financing headed by MMC Ventures, the Edinburgh, London and San Francisco-based company announced this morning. Legal & General played a major role in the raise as the heaviest backer and Current's first corporate investor, with additional funds coming from Par Equity and Scotting Investment Bank. The primary device of Current's monitoring platform is an FDA-cleared upper-arm wearable that tracks skin temperature, pulse rate, oxygen saturation, movement and other metrics. Patients using the platform receive the tracker alongside a tablet that provides a Q&A chatbot, educational content, medication reminders and support for video or text conversations with a clinician. These clinicians, meanwhile, can follow their patients' vitals through a provider-facing interface and intervene when necessary.
A person receives a test for diabetes during Care Harbor LA free medical clinic in Los Angeles, California September 11, 2014. DreaMed Diabetes, the Petah Tikva-based developer of personalized diabetes management solutions, has received US Food and Drug Administration (FDA) clearance for its artificial intelligence-powered insulin recommendations technology. The company's AI-based insulin dosing decision-support software, DreaMed Advisor Pro, aims to assist people with Type 1 diabetes (T1D) using insulin-pump therapy with continuous glucose sensors or blood glucose meters.
The need for new medications is higher than ever, but so is the cost and time to bring them to market. Developing a new drug can cost billions and take as long as 14 years, according to the U.S. Food and Drug Administration. Yet with all that effort, only 8 percent of drugs make it to market, the FDA said. "We need to make smarter decisions about which potential medicines we develop and test," said Abraham Heifets, co-founder of San Francisco-based startup Atomwise. The six-year-old company, a member of our Inception startup incubator program, is working to make that happen by using GPU-accelerated deep learning to predict which molecules are most likely to lead to treatments.
The US Food and Drug Administration (FDA) has cleared an artificial intelligence (AI) algorithm from GE Healthcare that analyzes chest x-rays for pneumothorax and helps flag suspected cases for radiologists to prioritize reading, the company announced today. The algorithm, part of a set of other quality-assurance algorithms named the Critical Care Suite, was developed to run on a GE Healthcare mobile x-ray device. The software is not yet for sale, and an outside expert expressed concern about its false positive rate. The idea for the application came from bedside clinician experience of waiting for radiologists to read chest x-rays, said Rachael Callcut, MD, MSPH, a surgeon and director of data science for the Center for Digital Health Innovation at the University of California, San Francisco. UCSF proposed developing the feature as part of a development partnership with GE Healthcare.
Elon Musk's secretive "brain-machine interface" startup, Neuralink, stepped out of the shadows on Tuesday evening, revealing its progress in creating a wireless implantable device that can – theoretically – read your mind. At an event at the California Academy of Sciences in San Francisco, Musk touted the startup's achievements since he founded it in 2017 with the goal of staving off what he considers to be an "existential threat": artificial intelligence (AI) surpassing human intelligence. Two years later, Neuralink claims to have achieved major advances toward Musk's goal of having human and machine intelligence work in "symbiosis". Neurolink says it has designed very small "threads" – smaller than a human hair – that can be injected into the brain to detect the activity of neurons. It also says it has developed a robot to insert those threads in the brain, under the direction of a neurosurgeon.